Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Stock Has Average Price Target of $112.74 According to Brokerages

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) have received a consensus recommendation of “Hold” from the twenty-four brokerages that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, sixteen have given a hold rating and seven have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $112.74.

ZBH has been the topic of several research reports. Royal Bank Of Canada boosted their price target on Zimmer Biomet from $110.00 to $125.00 and gave the company an “outperform” rating in a research note on Thursday, November 5th. Citigroup upped their price target on Zimmer Biomet from $99.00 to $117.00 and gave the company a “neutral” rating in a report on Thursday, November 5th. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research report on Wednesday, August 5th. Robert W. Baird set a $104.00 price objective on Zimmer Biomet in a report on Thursday, August 6th. Finally, UBS Group lifted their price objective on Zimmer Biomet from $120.00 to $130.00 and gave the stock a “buy” rating in a report on Thursday, November 5th.

Zimmer Biomet Stock Performance

NYSE ZBH opened at $107.47 on Wednesday. The company’s fifty day moving average is $95.42 and its two-hundred day moving average is $92.29. Zimmer Biomet has a 52-week low of $79.12 and a 52-week high of $112.54. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.46 and a quick ratio of 0.79. The firm has a market capitalization of $20.50 billion, a price-to-earnings ratio of 27.21, a P/E/G ratio of 2.54 and a beta of 0.50.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Wednesday, November 4th. The medical equipment provider reported $1.90 EPS for the quarter, beating analysts’ consensus estimates of $1.88 by $0.02. Zimmer Biomet had a net margin of 8.95% and a return on equity of 13.02%. The business had revenue of $2.06 billion during the quarter, compared to analyst estimates of $2.04 billion. During the same quarter in the prior year, the business earned $1.90 earnings per share. The firm’s revenue for the quarter was up 3.1% on a year-over-year basis. Equities research analysts forecast that Zimmer Biomet will post 8.56 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, October 30th. Investors of record on Wednesday, September 30th were given a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend was Wednesday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is 24.30%.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, insider Kevin R. Thornal sold 5,691 shares of Zimmer Biomet stock in a transaction on Friday, September 11th. The shares were sold at an average price of $92.95, for a total transaction of $528,978.45. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Chad Phipps sold 3,000 shares of the stock in a transaction on Friday, September 4th. The shares were sold at an average price of $98.35, for a total transaction of $295,050.00. Following the completion of the transaction, the insider owned 65,231 shares of the company’s stock, valued at approximately $6,415,468.85. This represents a 4.40% decrease in their position. The SEC filing for this sale provides additional information. 1.28% of the stock is owned by company insiders.

Institutional Investors Weigh In On Zimmer Biomet

Several large investors have recently modified their holdings of ZBH. Tacita Capital Inc bought a new position in shares of Zimmer Biomet during the 2nd quarter worth approximately $26,000. Ancora Advisors LLC acquired a new stake in Zimmer Biomet in the 2nd quarter valued at $29,000. Elevation Wealth Partners LLC grew its position in Zimmer Biomet by 145.9% in the second quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider’s stock valued at $33,000 after acquiring an additional 229 shares during the period. Cassaday & Co Wealth Management LLC bought a new stake in Zimmer Biomet in the first quarter valued at $44,000. Finally, Parvin Asset Management LLC acquired a new position in Zimmer Biomet during the second quarter worth $47,000. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc. develops and manufactures medical devices and technologies used in musculoskeletal care. Its products support orthopedic procedures involving the hip, knee, shoulder, and extremities, as well as trauma care, sports medicine, and related surgical applications. The company also offers surgical technologies, including robotic and digital solutions designed to assist clinicians with planning and performing procedures. Its products and services are used by hospitals, surgeons, and other healthcare providers.